GMAB compared with MCS: revenue, margins and what each company keeps, and the suppliers and customers both name

GMABGenmab A/S

Mkt capRevenueRevenue

MCSMarcus Corp

Mkt capRevenueRevenue

Compare

GMABGenmab A/S

MCSMarcus Corp

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

GMAB: latest quarter not drawable.Method ›

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only GMAB 1

COAGHemab Therapeuticscustomer

Shared 0

No disclosed counterparties: MCS.

Only MCS 0

None

Role chip = supplier or customerSource: SEC EDGAR

GMABGenmab A/S

55.55▼−2.64%

Mkt cap$36.7BRevenue—Revenue—

MCSMarcus Corp

26.63▲+0.29%

Regular sessionSep 2 '83

Mkt cap$825.5MRevenue$238MQ3 FY26Revenue$758MFY25

Compare

Regular sessionSep 2 '83

GMABGenmab A/S

MCSMarcus Corp

55.55▼−2.64%

Price

26.63▲+0.29%

$36.7B

Mkt cap

$825.5M

—

Revenue

$238MQ3 FY26

—

Revenue

$758MFY25

GMAB55.55▼−2.64%vsMCS26.63▲+0.29%Regular sessionSep 2 '83

Price

rebased to 0%

GMAB, solidMCS, dashed